IOVA News and Press, Iovance Biotherapeutics Inc. From 02/16/24

AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy AMTAGVI deploys patient-specific immune cells that recognize and fight cancer SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NE...

2024-02-16 15:00:59 ET More on the markets SPY Pullback Triggers Sell Signal (Technical Analysis) SPY: Up 14 Weeks Out Of Last 15 - I'm Out SPY: Larger Treasury Issuances And Fewer Fed Cuts Are Not Priced In Investors retract capital from the fund market for ...

2024-02-15 14:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-12 07:14:00 ET In investing and in life, it's rare for opportunities to be without accompanying risks, just as it's rare for clouds to be without silver linings if one looks hard enough. On that note, Iovance Biotherapeutics (NASDAQ: IOVA) is a biotech that's chock-full of u...

2024-02-08 07:27:00 ET As with most pre-revenue biotech companies, Iovance Biotherapeutics (NASDAQ: IOVA) has a lot to prove. With its cash reserves running low and its first therapies approaching their shot at reaching the market, hitting the ball out of the park would delight shar...

2024-02-07 05:10:00 ET Iovance Biotherapeutics (NASDAQ: IOVA) has reached a major turning point in its story as a company. Later this month, the U.S. Food and Drug Administration (FDA) is set to issue a decision on what could become the company's first commercialized product develop...

2024-02-04 06:27:00 ET Depending on which facts you choose to focus on, you could have widely varying opinions on Iovance Biotherapeutics (NASDAQ: IOVA) . From one perspective, it's an ailing biotech that's facing down the specter of serious -- potentially existential -- risks inher...

2024-01-25 09:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-21 12:04:40 ET Summary Iovance's tumor infiltrating lymphocyte cell therapy candidate, lifileucel, has shown promising results in a study of melanoma patients, with a 31.4% overall response rate. Lifileucel uses a novel mechanism of action to treat stage IV melanoma and ha...

2024-01-19 16:59:33 ET Summary Iovance Biotherapeutics is preparing for the extended FDA deadline to determine the approval of lifileucel for advanced melanoma treatment. The FDA has put a clinical hold on the company's Phase II study for LN-145, which has raised concerns about th...